Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study
Warren H. Capell, Elliot S. Barnathan, Gregory Piazza, Alex C. Spyropoulos, Judith Hsia, Scott Bull, Concetta Lipardi, Chiara Sugarmann, Eunyoung Suh, Jaya Prakash Rao, William R. Hiatt, Marc P. Bonaca
Topics & Concepts
MedicineRivaroxabanCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Intensive care medicineBetacoronavirusMEDLINEInternal medicineVirologyWarfarinDiseasePolitical scienceOutbreakAtrial fibrillationLawInfectious disease (medical specialty)COVID-19 Clinical Research StudiesVenous Thromboembolism Diagnosis and ManagementHeparin-Induced Thrombocytopenia and Thrombosis